Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

ABSTRACT:

Background

The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV) infection, so data regarding primary prevention strategies in this population are needed.

Methods

In this phase 3 trial, we randomly assigned 7769 participants with HIV infection with a low-to-moderate risk of cardiovascular disease who were receiving antiretroviral therapy to receive daily pitavastatin calcium (at a dose of 4 mg) or placebo. The primary outcome was the occurrence of a major adverse cardiovascular event, which was defined as a composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack, peripheral arterial ischemia, revascularization, or death from an undetermined cause.

Resul

SUBMITTER: Grinspoon SK 

PROVIDER: S-EPMC10564556 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature